Thomas Rubenak is senior principal of Accenture Ventures. Courtesy of Accenture

In most industries, there's a disconnect between startups and major corporations. The startups may have solutions for the big companies, but the two entities might not know how to connect with each other. That's something Accenture hopes to help with.

The company created Accenture Ventures to help connect the dots between emerging technology and big business. As the program has expanded, Thomas Rubenak was selected to serve the Southwest region as senior principal.

With a long career of working in tech, research and design, and startups, Rubenak hopes to use his experience to help grow Houston's blossoming innovation ecosystem.

"It takes a village. It's not just the amazing accelerators we have throughout the region," Rubenak says. "If you look at the Cannon, Houston Exponential, MassChallenge, and all of the ecosystem — it takes all of us together to prop up a thriving economy. That's what we're doing. We're changing not just the face of Houston but really impacting the startups as well as the clients we serve."

Rubenak spoke with InnovationMap to discuss the role Accenture Ventures plays in the ecosystem and how he sees innovation in Houston growing.

InnovationMap: You're new to your role, but you've worked with tech and startups for years. Tell me a little bit about your career to date. 

Thomas Rubenak: I come most recently from EY. I did a few assignments there, primarily working with the EY and Microsoft alliance. I was also a go-to-market lead for deep technical accounting for IPOs and other regulatory compliance issues. I worked a lot with the Entrepreneur of the Year program. Before that, I spent most of my career in tech research with Gartner and Forrester. This space is all about brilliant minds that really focus on helping the world understand what's next in emerging technology. I worked pretty extensively with venture capital, private equity and venture banks.

IM: While you’ve worked on projects across the country, you’ve been based in Houston, so you’ve been able to see the city transform, right?

TR: In my career, I've been really fortunate enough to align with amazing people in the market. Several years ago, we started a community just in Houston to bring entrepreneurs, angel investors, and some VC together. It was a nonprofit, grassroots effort called TeXchange; I just wanted to help entrepreneurs connect to sources of capital.

IM: How did Accenture Ventures get its start and what does it aim to do?

TR: Accenture realized four years ago that in order to stay competitive, it needed to tap the best of the best in the startup world. The only way to do that is to dedicate resources and people to that task, and that's how we started Ventures. As a recent joiner, my role is primarily the lead for the Southwest to bring the best of the startup ecosystem into our clients to help them solve their most pressing problems. And it's not just about problems, but also about opportunities.

It's a win-win-win. The client gets the benefit of having the best of the best and the startups get amazing exposure to companies they might not have been able to get in front of. And, Accenture is happy because it gets to serve the client.

Accenture works in multiple sectors, including resources (oil and gas), chemicals, mining — so for obvious reasons, the Southwest is a big sector for us — but, we also tap the health and public safety sectors.

As we look to design these arrangements with these startups and we find that there is a compelling need to invest in them, we'll become a minority investor. If that startup then has a M&A play that makes sense to everyone, we'll look into that as well.

IM: How do Accenture Ventures and the Innovation Hub work together?

TR: I am part of the hub, and I also serve the broader team.

What we bring to the table is amazing talent to data scientists to designers — many different resources — and we work with our clients to figure out what they want to solve or if there's a play in the market they are interested in. We can pull the best from Accenture and from the startup ecosystem to design solutions.

IM: What’s the most challenging thing about solving clients’ goals?

TR: It's not a challenge so to speak, but it's something I have to be mindful of, and that is always keeping the client's interest at hand, so recognizing and realizing that they have short- and long-term goals that they want to achieve.

IM: What's it like working with companies on the startup side?

TR: We seek specific types of startups. In order for us to be really effective, we keep a pulse on the market. Our focus is on companies that have gotten their source of funding, they've gone through their first round, companies that have great management who have been in industry or served big companies, and companies that are disruptors, innovators, or have something really compelling to bring to us. The challenge is that there are so many of them. There are so many great startup companies doing amazing things. But, as many startups as there are, there's just as many client issues.

IM: In your opinion, what challenges does the Houston innovation ecosystem still have to overcome?

TR: It's no secret that the economic engine of venture capital is in the east and west coasts. We have a lot of great VCs here, but it's about how do we keep our startups here. That's an issue that everyone talks about. But we also have seen a lot of startups move to Houston from other places. But, from the financial aspect of it, I think we could always use more of that. I personally don't think there will ever be another Silicon Valley, but we'll be something different. We'll be ourself. But, we do need those sources of capital in place. But something I want to mention is the diversity and the universities in Houston — we have a lot going for us.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

UH lab using mixed reality to optimize designs for the Moon and Mars

hi, tech

University of Houston researchers and students are bringing multiple realities together to help improve the design process for crewed space missions.

Helmed by Vittorio Netti, a researcher for UH and a space architect, the university has launched an XR Lab within the University of Houston architecture building. The lab allows researchers to combine mixed reality (MR), virtual reality (VR), augmented reality (AR) and extended reality (XR) to "blend the physical and digital worlds" to give designers a better understanding of life in space, according to a release from UH.

In the lab researchers can wear MY space suits and goggles, take a VR space walk, or feel what it's like to float to the International Space Station with the help of XR and a crane.

The area in which the researchers conduct this work is known as the "cage" and was developed during a six-month research and design study of lunar surface architecture sponsored by Boeing, which aimed to learn more about the design of a lunar terrain vehicle and a small lunar habitat.

The work is part of UH's Sasakawa International Center of Space Architecture (SICSA), which is led by Olga Bannova, a research associate professor and director of the space architecture graduate program at UH.

She says work like this will drastically cut down research and development time when designing space structures.

“These technologies should be harnessed to mitigate the dependency on physical prototyping of assets and help optimize the design process, drastically reducing research-and-development time and providing a higher level of immersion,” Bannova said in a statement.

Today the research team is shifting its focus on designing for a Mars landing. In the future, they aim to demonstrate and test the system for habitats designed for both lunar and Martian surfaces. They are also working with Boeing to test designs in microgravity, or zero gravity, which exists inside the International Space Station.

Mixed Reality Raising the Bar for Space Architecture on the Moon and MarsStep into this 'Cage' at the University of Houston where physical and digital worlds are merged, allowing students to see and ...